Navigation Links
Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
Date:12/17/2007

overall aim to improve people's health and quality of life. Based on its policy of continuous expansion throughout the world, Ferrer has established strong industrial and commercial operations in Europe and has extensive commercial experience in Latin America, Africa, and in the Middle and Far East. Ferrer has licensing, distribution, and marketing agreements with large multinational pharmaceutical companies, as well as mid-size firms, including AstraZeneca, Astellas, Johnson & Johnson, Merck Sharp & Dohme, Novartis, Roche, Sanofi-Aventis, Solvay, Cephalon, United Therapeutics, and The Medicines Co., among others.

In addition to its commercial operations, Ferrer operates pharmaceutical research and development facilities in Barcelona, Spain and Alsdorf, Germany. The research facilities in Barcelona manage all aspects of drug development from concept through to clinical development and product registration. The Alsdorf facility is specialized in new applications of pharmaceutical technology. Ferrer also has established research collaborations with a large number of pharmaceutical companies and universities throughout the world.

About Vasogen:

Vasogen is a biotechnology company engaged in the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. The Company's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade is in late-stage development for the treatment of chronic heart failure and has received European regulatory approval under the CE Mark for this indication. Vasogen is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

Certain statements contained in this press release or else
'/>"/>

SOURCE Vasogen Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Israel , June 18, 2013 ... Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage ... the company has been granted a United States ... US and Europe for the oral ... 8,410,176 B2 is titled Intermediate Compounds and Processes for ...
(Date:6/18/2013)... 2013 This webinar will examine ... and promotion, and review the basic FDA regulations ... to apply these principles through real world case ...     The fundamentals on FDA regulations and guidance related ...     Assessing traditional and newer forms of promotional ...
(Date:6/18/2013)... , June 18, 2013 ... ) has announced the addition of the ... [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & ... & Auto Injectors] & Therapeutics [Diabetes & ... report to their offering.      ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 As ... MeMD, Inc proudly announces the release of their ... and Fitness ". , MeMD's goal was to ... landscape of Health 2.0, Health 3.0 and mHealth.The ... likely transform medical care and the fitness industry ...
Breaking Biology Technology:Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3MeMD, Inc Releases Infographic Featuring the Top Eight Technologies that are Revolutionizing Health and Fitness Today 2
... Every year, millions of people contend with lower back ... Cornell University engineers in Ithaca and doctors at the ... created a biologically based spinal implant that could someday ... Bonassar, Ph.D., associate professor of biomedical engineering and mechanical ...
... health condition that can lead to damaged heart tissue ... peripheral arterial disease in limbs, amputation, particularly in diabetic ... novel nanostructure that promotes the growth of new blood ... where increased blood flow is needed to supply oxygen ...
... Flexible, transparent electronics are closer to reality with the ... The lab of Rice chemist James Tour lab has ... panels and LED lighting. The research was reported in ... Flexible, see-through video screens may be the "killer app" ...
Cached Biology Technology:In the battle to relieve back aches, Cornell researchers create bioengineered spinal disc implants 2In the battle to relieve back aches, Cornell researchers create bioengineered spinal disc implants 3Restoring blood flow 2Restoring blood flow 3Dream screens from graphene 2Dream screens from graphene 3
(Date:6/18/2013)... Council, Laboratory of Molecular Biology, has been honored ... Investigator Award. Torrent is being recognized for his ... to predict antimicrobial regions in proteins. Luis Rivas, ... applying this algorithm to interrogate full genomes in ... very appealing results." , Torrent obtained his ...
(Date:6/18/2013)... extract of a yellow-flowered mountain plant long used for ... fruit fly populations by an average of 24 percent, ... Rhodiola rosea , also known as ... study leaders Mahtab Jafari and Sam Schriner. They discovered ... unrelated to dietary restriction and affects different molecular pathways. ...
(Date:6/18/2013)... shows that weight gain and increased head size in the ... IQ at early school age. , The study was led by ... than 13,800 children who were born full-term. , The results, published ... who put on 40% of their birthweight in the first four ... were six years of age, compared with babies who only put ...
Breaking Biology News(10 mins):The American Society for Microbiology honors Marc Torrent 2Herbal extract boosts fruit fly lifespan by nearly 25 percent, UCI study finds 2IQ link to baby's weight gain in first month 2
... carrot has been produced to help people absorb more calcium. ... Improvement Center studied the calcium intake of humans who ate ... The research, which was done in collaboration with Baylor College ... help prevent such diseases as osteoporosis. If you ...
... UBC researchers have discovered some of the genetic ... fight off pests and disease, uncovering critical new ... Prof. Joerg Bohlmann says this genetic analysis will ... inherent strength, breeding trees that could in time ...
... 14, 2008) Reporting in the online journal BMC Genetics, ... attempted to count the number of genes that contribute to ... over 6,000 genes about 25 percent of the genome ... describing the discovery of a new obesity gene have become ...
Cached Biology News:Got carrots? Vegetables may have bone to pick as calcium providers 2UBC discovery unlocks tree genetics, gives new hope for pine beetle defense 2Body weight influenced by thousands of genes 2
EGTA, 10 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
UV LAMP 254 NM 8 WATT, 1 EA. Category: Nucleid Acid Detection Systems....
... The SelectFX Alexa Fluor 488 Cytochrome c ... you need to detect cytochrome c in ... c primary antibody and an Alexa ... 488 dye exhibits bright green fluorescence that ...
Biology Products: